Welcome to our dedicated page for Syneos Health news (Ticker: SYNH), a resource for investors and traders seeking the latest updates and insights on Syneos Health stock.
Company Overview
Syneos Health (SYNH) stands as the only fully integrated, end-to-end clinical and commercial solution organization in the biopharmaceutical industry. Originating from a strategic merger that brought together clinical research expertise and inventive commercial solutions, the company is purpose-built to accelerate drug development and commercialization for both emerging biotech innovators and established global pharmaceutical companies. With a robust framework that merges clinical excellence with commercial acumen, Syneos Health navigates the complexities of the modern biopharmaceutical market by providing seamless, data-driven support across all phases of a product lifecycle.
Integrated Clinical and Commercial Services
At its core, Syneos Health offers a comprehensive suite of services that encompass clinical research, commercialization strategies, and data analytics. The company is designed to ensure that every stage of clinical trial management—from study design to regulatory compliance and patient engagement—is integrated with commercial strategies that drive market success. This integration provides clients with the unique benefit of a single point of contact that can streamline operations and reduce time-to-market, thereby enhancing overall efficiency and effectiveness.
Operational Excellence and Data-Driven Insights
Syneos Health leverages a rich repository of data and advanced analytical tools to generate insights that are critical to optimizing clinical trial outcomes and commercial strategies. By applying a methodical, evidence-based approach, the company equips its clients with actionable insights that facilitate smarter decision-making, improve operational processes, and help mitigate risks inherent in clinical research and market entry.
Market Position and Competitive Differentiation
Within the competitive landscape of the biopharmaceutical industry, Syneos Health differentiates itself by seamlessly merging clinical and commercial expertise. This unique position enables the company to offer services that not only bring drugs to market but also optimize their market performance through a balanced, integrated approach. Key to its strategy is the focus on accelerating product development cycles and streamlining commercialization processes, which ultimately supports clients in meeting the critical needs of patient care and market demands.
Service Offerings and Strategic Value
- End-to-End Solutions: From early-phase clinical trials to post-launch commercialization support, the company offers a full spectrum of capabilities.
- Data-Driven Decision Making: Cutting-edge analytics provide clients with clear, actionable insights that shape their strategic roadmap.
- Operational Integration: A unified service delivery model minimizes redundancies, promotes efficiency, and reduces costs across operations.
- Tailored Approaches: Customized solutions ensure that both innovative startups and established multinational firms receive the precise support they require.
Expertise and Industry Impact
Syneos Health is renowned for its expertise, deep industry experience, and rigorous approach to clinical and commercial operations. By continuously advancing its methodologies and tools, it remains adaptable to the evolving demands of the biopharmaceutical market. Its ability to provide relevant, high-quality insights has firmly established its reputation as an expert partner in the healthcare ecosystem, making it a critical component in accelerating the pace of pharmaceutical innovation.
This integrated approach not only helps in reducing the risks and uncertainties associated with drug development but also supports a smoother path to commercialization. Each service component is designed to reinforce the other, ensuring that the overall solution is greater than the sum of its parts. Investors and industry analysts recognize Syneos Health as a key facilitator in bridging the gap between innovative drug development and successful market execution.
Syneos Health (Nasdaq:SYNH) will announce its third quarter 2020 financial results on October 29, 2020, before the earnings call at 8:00 a.m. ET. The call will be accessible via webcast on the company's Investor Relations website or by phone using the designated numbers. An audio replay will be available for a week post-call. Syneos Health is a fully integrated biopharmaceutical solutions organization with a global reach, combining clinical and commercial expertise to expedite the delivery of therapies to patients.
Syneos Health (Nasdaq: SYNH) announced a secondary offering of 7,000,000 shares at $59.75 per share, with an expected close on September 17, 2020. The sale is led by affiliates of Thomas H. Lee Partners and Advent International, with Syneos not receiving any proceeds from the offering. The company also agreed to repurchase approximately $30 million worth of its shares from the underwriters at the same share price. Goldman Sachs & Co. LLC and Morgan Stanley are the underwriters for this offering.
On September 15, 2020, Syneos Health (SYNH) announced a secondary offering of 7,000,000 shares of its common stock by affiliates of Thomas H. Lee Partners and Advent International. The company will not sell any shares or receive proceeds from this offering. It has agreed to repurchase approximately $30 million of the shares from the underwriters at the offering price. Goldman Sachs and Morgan Stanley are the underwriters for the transaction. Investors are encouraged to review the registration statements and prospectus available on the SEC website for further information.
MORRISVILLE, N.C., Sept. 9, 2020 – Syneos Health (Nasdaq: SYNH) announced a rescheduling of its presentation at the Baird 2020 Global Healthcare Conference due to technical glitches. CEO Alistair Macdonald and CFO Jason Meggs will present today at 12:15 p.m. ET. A live webcast and presentation materials will be available on the Company’s Investor Relations website, enhancing accessibility for stakeholders.
Syneos Health is a fully integrated biopharmaceutical solutions organization, combining a CRO and CCO, dedicated to improving customer performance globally.
Syneos Health (Nasdaq: SYNH) announced that CEO Alistair Macdonald and CFO Jason Meggs will present at the Baird 2020 Global Healthcare Conference on September 9, 2020, at 8:30 a.m. ET. A live webcast of the event, along with presentation materials and an archived audio replay, will be accessible on the Company's Investor Relations website.
Syneos Health is a fully integrated biopharmaceutical solutions organization, combining a Contract Research Organization (CRO) and a Contract Commercial Organization (CCO), serving over 110 countries with approximately 24,000 professionals.
Syneos Health (SYNH) reported a GAAP revenue of $1,013.4 million for Q2 2020, down 13.1% year-over-year. Net new business awards totaled $1,360.9 million, resulting in a book-to-bill ratio of 1.34x. The Clinical Solutions segment saw a revenue decline of 12.1% to $747.2 million, while Commercial Solutions dropped 16.0% to $266.2 million. Despite challenges from COVID-19, the company issued full-year guidance of $4,470 million to $4,570 million in revenue, along with adjusted EBITDA expectations of $600 million to $640 million.
Syneos Health (Nasdaq: SYNH) has signed a new three-year agreement with Pfizer to provide global product development solutions. This partnership strengthens their existing relationship, with a provision for Pfizer to extend the agreement by two additional years. Financial details are undisclosed. The collaboration will leverage Syneos Health's therapeutic expertise to optimize Pfizer's portfolio, ensuring efficient product development and trial processes.
Syneos Health (Nasdaq: SYNH) will announce its second quarter 2020 financial results on August 6, 2020, before an earnings call at 8:00 a.m. ET. The call can be accessed via webcast on the company's website or by telephone. Syneos Health, a fully integrated biopharmaceutical solutions organization, aims to enhance customer performance in over 110 countries, utilizing advanced technologies and insights to expedite crucial therapies to patients. A replay of the call will be available shortly after, along with audio access for a week.
MORRISVILLE, N.C., May 22, 2020 (GLOBE NEWSWIRE) -- Syneos Health (Nasdaq: SYNH) announced that CEO Alistair Macdonald and CFO Jason Meggs will present at two investor conferences. The events are the Jefferies Virtual Healthcare Conference on June 3, 2020, at 9:30 a.m. ET, and the William Blair 40th Annual Growth Stock Conference on June 9, 2020, at 9:00 a.m. ET. Live webcasts and presentation materials will be available on the Company’s Investor Relations website.
Syneos Health is a fully integrated biopharmaceutical solutions organization, combining a CRO and CCO.
FAQ
What is the market cap of Syneos Health (SYNH)?
What is the core business of Syneos Health?
How does Syneos Health integrate its services?
Who are the primary clients of Syneos Health?
What sets Syneos Health apart from other service providers?
How does Syneos Health utilize data in its operations?
Can Syneos Health support both clinical and market launch phases?
What industries does Syneos Health primarily serve?
How does the integrated model benefit its clients?
